Haima
2 known investors
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders. Its lead technology, SynthoPlate, is a fully-synthetic hemostatic agent that acts at the injury site to amplify the body's natural clotting mechanisms.
Founders & leadership
AS
Anirban Sen GuptaCTO
MB
Michael BruckmanCEO
MN
Matthew NealCMO
CP
Christa PawlowskiCOO and EVP of R&D
TP
Timothy PeluraExecutive Chair
Investors · 2
Competitors · 1
by search overlapCompanies competing with Haima for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Haima do?
- Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders. Its lead technology, SynthoPlate, is a fully-synthetic hemostatic agent that acts at the injury site to amplify the body's natural clotting mechanisms.
- Who founded Haima?
- Haima was founded by Anirban Sen Gupta.
- Who are Haima's investors?
- Haima's investors include CWRU Technology Ventures, Tachyon Ventures.